Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Completed · Phase 3

Conditions studied: Epilepsy

In brief

The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.

Key facts

Study ID

NCT01191086

Run by

Upsher-Smith Laboratories

People needed

210

Starts

2010-10-01

Expected to finish

2014-05-01

Last updated by the study team

2015-02-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have completed the maintenance period of the P09-004 study.
• Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.

Where it is running

• Study site — Ventura, California, United States
• Study site — Gainsville, Florida, United States
• Study site — Gulf Breeze, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Port Charlotte, Florida, United States
• Study site — Lexington, Kentucky, United States
• Study site — Waldorf, Maryland, United States
• Study site — Chesterfield, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Somerset, New Jersey, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Toledo, Ohio, United States
• Study site — Dallas, Texas, United States
• Study site — Temple, Texas, United States
• Study site — Milwaukee, Wisconsin, United States
• Study site — Buenos Aires, Argentina
• Study site — Córdoba, Argentina
• Study site — Salta, Argentina
• Study site — Villa Nueva, Argentina
• Study site — Bedford Park, Australia
• Study site — Clayton, Australia
• Study site — Fitzory, Australia
• Study site — Heidelberg West, Australia
• Study site — Parkville, Australia
• Study site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.